# Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Study · id `cardio:ct-nct07017270` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07017270](<https://clinicaltrials.gov/study/NCT07017270>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07017270

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07017270. Randomized; no masking; primary purpose treatment. Start 2025-11-27 (actual); primary completion 2027-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07017270, source copy `cardio:ctgov-nct07017270-2026-06-26`, retrieved 2026-10-26)
- Started: 2025-11-27 (actual) (ClinicalTrials.gov record NCT07017270, source copy `cardio:ctgov-nct07017270-2026-06-26`, retrieved 2026-10-26)
- Primary completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT07017270, source copy `cardio:ctgov-nct07017270-2026-06-26`, retrieved 2026-10-26)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT07017270, source copy `cardio:ctgov-nct07017270-2026-06-26`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT07017270, source copy `cardio:ctgov-nct07017270-2026-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07017270-2026-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
- Acronym: GUARD-1
- Condition: Kidney Disease, Chronic
- Condition: Diabetes
- Condition: Dialysis
- Condition: End Stage Kidney Disease (ESRD)
- Intervention (Drug): Semaglutide Pen
- Lead sponsor: Unity Health Toronto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Unity Health Toronto (`cardio:org-unity-health-toronto`)

## Provenance

Content hash: 97fd1e3585d5b6a9f5cb803a774816c6ceb54c8c1e152dba93e3c4ebf36aa93e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
